Cannabis Science Provides Product Line Guidance With Summary of Products In Development And Available On The Market Today
24 April 2012 - 7:45PM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana) products, is
providing an update and summary of our goals and product line
advancements. Some products are currently available to patients
with legal state medical marijuana access, and others are up and
coming over-the-counter products that will be available to the
public nationally and internationally.
Cannabis Science is currently working towards making critical
cannabis-based medications more widely available. To this aim, we
have initiated, with our FDA advisory group, the pre-IND process.
Unlike most conventional treatments, cannabis medicines and
formulations have an outstanding safety profile, going back
thousands of years. They allow patients in states with medical
cannabis laws to safely make informed decisions to legally
self-administer various cannabis-based preparations.
The medication will specifically target skin cancers including
basal and squamous cell carcinomas. Judging by the results of the
squamous cell carcinoma treatment studies Cannabis Science has
already undertaken (see cannabisscience.com), we believe we have a
breakthrough treatment for squamous cell carcinomas that are
resistant to convention chemo- and radiation therapies.
Currently, Cannabis Science has cannabis-based, high quality oil
available in Pueblo and Denver Colorado through licensing
agreements. The oil, is packaged in oral dispensing syringes for
patient self-administration. We have received excellent feedback
regarding these products, specifically from patients suffering
cancer and chronic pain.
In addition to the license agreements with dispensary and FDA
products, Cannabis Science is very excited about the over the
counter skin and nutraceutical product lines that are currently in
development. Sunscreen, skin and face moisturizer, lip balm, and
anti-aging serum will be available over the counter in drugstores
and other retail outlets. Dr. Moe Afaneh, Cannabis Science’s Chief
Operations Officer, is heading the development of this product
line, and with his decade of successful experience in
pharmaceutical product marketing, branding, and compounding
prescriptions, he is aiding Cannabis Science tremendously in moving
these projects forward. Cannabis Science is also in final
discussions to finalize the brand name for the initial product
line.
The Company's intent is to work with specially appointed legal
providers and laboratories to expand the availability of its
formulations across the United States and the world where legally
available.
Dr. Bob Melamede stated “Cannabis Science is excited that we are
developing profit centers that will come online and create revenue
in 2012. In addition to the revenues that we believe will be
created with the Cannabis Extract Based prescription medicines and
over-the-counter formulations, Cannabis Science has the ability to
generate revenues now through the partnership with Vincent
Mehdizadeh of Medical Dispensing Solutions, and consulting revenues
Kaneabis acquisition. It is our goal to self- fund the FDA IND
application and approval process as much as possible, that funding
is generated from these additional profit centers.”
About Cannabis Science, Inc.Cannabis Science, Inc. is at
the forefront of pharmaceutical grade medical marijuana research
and development. The second formulations will address the needs of
patients choosing to use concentrated cannabis extracts to treat
their ailments. Eventually, all Americans will have access to a
safe and effective FDA approved medicine regardless of which state
they live in. To maintain that marijuana is a dangerous, addictive
drug with no medical value is scientifically absurd. Cannabis
medicines, with no effective lethal dose, are far safer than
aspirin, acetaminophen, and most other OTC drugs that kill
thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
www.cannabisscience.com
Forward Looking StatementsThis Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.